Literature DB >> 1355665

Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1355665     DOI： 10.1007/bf00054195

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  10 in total

1.  Renal effects of fenoldopam in refractory hypertension.

Authors:  L M Ruilope; R G Robles; B Miranda; J Tovar; J M Alcazar; J Sancho; J L Rodicio; A Martinez; A Astorga; T Beck
Journal:  J Hypertens       Date:  1988-08       Impact factor: 4.844

2.  Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.

Authors:  H O Ventura; F H Messerli; E D Frohlich; I Kobrin; W Oigman; F G Dunn; R M Carey
Journal:  Circulation       Date:  1984-06       Impact factor: 29.690

3.  Effects of fenoldopam, a specific dopamine receptor agonist, on blood pressure and left ventricular function in systemic hypertension.

Authors:  M P Caruana; M Heber; G Brigden; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

4.  Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension.

Authors:  W B White; S E Halley
Journal:  Arch Intern Med       Date:  1989-04

5.  Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine receptors.

Authors:  M F Lokhandwala; H O Watkins; M H Sabouni; K A Alkadhi
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

6.  Studies with fenoldopam, a dopamine receptor DA1 agonist, in essential hypertension.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

7.  The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man.

Authors:  J N Harvey; D P Worth; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

8.  Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

Authors:  R R Weber; C E McCoy; J A Ziemniak; E D Frederickson; L I Goldberg; M B Murphy
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

9.  Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam.

Authors:  W B White; M J Radford; F M Gonzalez; S G Weed; E J McCabe; A M Katz
Journal:  J Am Coll Cardiol       Date:  1988-05       Impact factor: 24.094

10.  The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; G Martin; D Redman; S Hasan; P Sever
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335
  10 in total
  1 in total

Review 1.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.